WHO ICTRP trial
ALKAZAR
JPRN-jRCT2071250073 · Japan Primary Registries Network (JPRN) · Not Recruiting
Key facts
| Trial ID | JPRN-jRCT2071250073 |
|---|---|
| Public title | ALKAZAR |
| Scientific title | A Phase 3 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 Compared to Alectinib in First-Line Treatment of Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer - ALKAZAR |
| Primary sponsor | Tsutsui Toshio |
| Registry | Japan Primary Registries Network (JPRN) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | 3 |
| Countries | USA;Japan;Taiwan;Japan;Korea;Japan;Singapore;Japan;Australia;Japan;Canada;Japan;Thailand;Japan;Malaysia;Japan;Chile;Japan;Argentina;Japan;Mexico;Japan;Brazil;Japan;Hong… |
| Conditions | Advanced ALK-positive non-small cell lung cancer |
| Interventions | Patients will receive 150 mg of NVL-655 orally once daily, or 600 mg of Alectinib orally twice daily, and continue treatment until symptomatic deterioration, development of unacceptable toxicity, or other discontinuation criteria are met… |
| Registration date | Sep 25, 2025 |
| Target size | 45 |
| Secondary IDs | NCT06765109 |
| Registry page | jrct.mhlw.go.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: